I and others have urged moderation in your posting. I have no beef with enthusiasm or conviction, but it is simply not necessary to keep littering this BB with endless reworking of the same limited content. You have made your points clear - we understand your position (regardless of whether we agree or not) - So please do not keep posting the same content. By all means post fresh research or observation, but if you keep up this endless rehashing of what you said earlier today (on numerous occasions), yesterday and the day before etc, so are simply becoming background static which will get filtered both metaphorically and practically.
in the short-term, there "is the possibility of Aur+FLT3 being granted an EU patent. The first half of next year brings the prospect of an Aur+FLT3 co-development deal, which we believe could be significant for the company. There is also the possibility of further news on the TYK2 project, with SRI publishing pre-clinical data on its psoriasis study. The FASN study, funded by a TSB Biomedical Catalyst grant, should produce pre-clinical data in H1/2014.
In the second half of 2014, we expect the TYK2 project to nominate a lead candidate. This should be followed by the IND filing for the CHK1 compound in late 2014/early 2015."
Mind you - this is the same house broker that in July 2012 forecast £4.3m in revenues in the year to June 2013, rising to £12.9m in the year ending June 2014. Now, 18 months on, it has sales forecasts out to 2016 all of which are zero.
And a final point - it is impossible to call this stock 'cheap' and comments such as " having all agreed that the Mcap is very undervalued " are just wrong and misleading.
It certainly has potential (why I'm invested) with the potential for significant value, whilst the collarborations/partnerships are definitely interesting. But with no revenues, cashflow or earnings forecast for at least the next two years it cannot ever be described as cheap.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.